Related Experiment Video
Updated: Jun 11, 2025
Detection of SARS-CoV-2 Receptor-Binding Domain Antibody using a HiBiT-Based Bioreporter
Published on: August 12, 2021
AI-based antibody discovery platform identifies novel, diverse, and pharmacologically active therapeutic antibodies
Cristina Moldovan Loomis1, Thomas Lahlali2, Danielle Van Citters1
1Department of Discovery & Molecular Design, Just-Evotec Biologics Inc., 401 Terry Avenue N., Seattle, WA 98109, USA.
Background:
We are entering a new era of antibody discovery and optimization where machine learning (ML) processes will become indispensable for the design and development of therapeutics.
Methods:
We have constructed a Humanoid Antibody Library for the discovery of therapeutics that is an initial step towards leveraging the utility of artificial intelligence and ML. We describe how we began our validation of the library for antibody discovery by isolating antibodies against a target of pandemic concern, SARS-CoV-2. The two main antibody quality aspects that we focused on were functional and biophysical characterization.
Results:
The applicability of our platform for effective therapeutic antibody discovery is demonstrated here with the identification of a panel of human monoclonal antibodies that are novel, diverse, and pharmacologically active.
Conclusions:
These first-generation antibodies, without the need for affinity maturation, exhibited neutralization of SARS-CoV-2 viral infectivity across multiple strains and indicated high developability potential.
